Annual Secretarial Compliance Report for y.e. 31-03-2025 is enclosed herewith
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals has submitted its Annual Secretarial Compliance Report for FY ended March 31, 2025, as required under SEBI LODR Regulation 24A. The report, issued by Rishi Mittal & Associates (Practicing Company Secretaries), confirms that the company has generally complied with applicable SEBI regulations, secretarial standards, and listing requirements during the review period. One new minor non-compliance was noted: a 1-day delay in submitting the XBRL-format secretarial compliance report for FY 2023-24, for which BSE levied a penalty of Rs. 2,360, which has been paid. Previous-year observations (delays in annual report submission, AGM proceedings filing, and IEPF shareholder notices) have been addressed, with the earlier annual report delay penalty of Rs. 4,720 also paid. The report confirms no SEBI or stock exchange action against the company, no director disqualifications, and proper audit committee approval of related party transactions.
This is a routine annual compliance filing with no material impact on shareholders. The penalties mentioned (Rs. 2,360 and Rs. 4,720) are negligible in size and have already been paid, indicating only minor administrative delays rather than any governance or financial concerns.